Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Zealand Pharma A/S (ZELA)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
622.00 +23.00    +3.84%
26/04 - Closed. Currency in DKK ( Disclaimer )
Type:  Equity
Market:  Denmark
ISIN:  DK0060257814 
S/N:  62648011
  • Volume: 189,605
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 598.50 - 622.00
Zealand Pharma 622.00 +23.00 +3.84%

Zealand Pharma A/S Company Profile

 
Get an in-depth profile of Zealand Pharma A/S, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

253

Equity Type

ORD

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

Contact Information

Address Sydmarken 11 SOeborg
Copenhagen, 2860
Denmark
Phone 45 88 77 36 00
Fax 45 88 77 38 98

Top Executives

Name Age Since Title
Gudmund Tyge Korsgard 67 - Board Observer
Richard E. Pratley - 2011 Member of Advisory Board
Bernard Charbonnel - 2011 Member of Advisory Board
Gert Van Assche - 2011 Member of Advisory Board
Ake Lernmark 79 2011 Member of Advisory Board
Paul Dorian - 2011 Member of Advisory Board
Bernadette Mary Connaughton 66 2019 Independent Director
Kirsten Aarup Drejer 68 2018 Independent Vice Chairman
Alf Gunnar Martin Nicklasson 69 2014 Independent Chairman of the Board
Jeffrey Berkowitz 58 2019 Independent Director
Leonard Kruimer 66 2019 Independent Director
Nikolaj Frederik Barfoed Beck 57 2020 Employee Representative Director
Katja Hansen - 2024 Alternate Director
Adam Nygaard - 2024 Employee Representative
Cecilie Kold - - Alternate Director
Ludovic Otterbein - 2024 Employee Representative
Anneline Nansen 55 2021 Employee Representative Director
Enrique A. Conterno Martinelli 58 2023 Member of Advisory Board & Director
Lars Pedersen - 2024 Alternate Director
Tanja Erichsen - 2024 Alternate Director
Elaine Sullivan 63 2023 Director & Member of Advisory Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ZELA Comments

Write your thoughts about Zealand Pharma A/S
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Giuseppe Giannachi
Giuseppe Giannachi Feb 27, 2024 5:13AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Can this be the alternative to Novo Nordisk and Eli Lily?
Karsten Vester
Karsten Vester Feb 27, 2024 5:13AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Way way behind in relation to production facilities and only in phase 2 and no study on good side effects (Select study) so not as of now.
Mette Og Jesper Erle
Mette Og Jesper Erle Dec 10, 2018 11:51AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Nice shoot up to Day 7,30 %
Kjeld Poulsen
Kjeld Poulsen Jul 03, 2015 6:05AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
New target is 145 during the second half of 2015.
Kjeld Poulsen
Kjeld Poulsen Apr 01, 2014 8:49AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I expect positive news during the coming months. A potential shs signal is forming with neckline 78 and target 97.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email